Abstract library

1025 results for "prior treatment".
#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)
Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Raymond
#2169 Patient and Clinician Perspectives on Symptom Priorities Across the Spectrum of Neuroendocrine Tumors (NETs)
Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Research Prof Kimberly Webster
#25 Predictors of response to radio-embolization (TheraSphere ®) treatment of neuro-endocrine liver metastasis
Introduction: Neuroendocrine tumors (NET) frequently metastasize to the liver. Most patients have diffuse, and therefore incurable, disease. NET liver metastasis has been shown to respond to yttrium-90 microspheres therapy. This study aims to define factors that predict response to radio-embolization in patients with NET liver metastases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Mazen Hassanain
#1496 Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-differentiated Neuroendocrine Tumors Resistant to Prior Treatments
Introduction: Alternating treatment with sunitinib and everolimus, has been shown to be efficacious in renal cell carcinoma
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Angelousi
#1011 Predictive Factors for Progression Free Survival (PFS) in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNET) Treated with Sunitinib
Introduction: Sunitinib and everolimus were approved for treatment of progressive PNET based on phase III trial data. However, features that may influence outcome with these antitargets have not been well-established.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula J Fonseca
#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Anamika Gulati
Authors: Yao J C, Fazio N, Li D, Pavel M, ...
Keywords: PDR001, immunotherapy, NET
#352 Predictive factors of tumor control in patients with well differentiated digestive endocrine carcinomas (WDEC) treated with lanreotide
Introduction: The antiproliferative effect of somatostatin analogs was recently demonstrated.
Conference:
Category: Basic
Presenting Author: Dr maxime palazzo
#568 Efficacy of Everolimus and Tolerability with Long-Term Use
Introduction: Predictors of response to Everolimus in neuroendocrine tumors and long-term safety data are lacking.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Maximilian Heetfeld
#732 Impact of Prior Chemotherapy (CT) and Somatostatin Analogues (SSAs) on Clinical Outcome in Well-Differentiated Pancreatic Neuroendocrine Tumors (pWDNETs) before Treatment of Everolimus (EV)
Introduction: In the phase III RADIANT-3 trial, EV demonstrated a significant improvement in PFS with a median of 11.0 v. 4.6 months (mo) for placebo in pWDNETs pts.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Pusceddu
Keywords: everolimus
#1797 An Open-Label Phase II Study to Evaluate the Efficacy and Safety Of PDR001 in Patients with Advanced Well-Differentiated Non-Functional NET of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Who Have Progressed on Prior Treatment
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti-PD-1 and anti-PD-L1, have become established treatment (tx) options in various solid tumors. However, there is a paucity of data on checkpoint inhibitors in NET. In a phase I trial of PDR001 (mAb checkpoint inhibitor targeting PD-1) conducted in patients (pts) with multiple solid tumor types, a pt with histologically confirmed metastatic atypical pulmonary carcinoid demonstrated a RECIST-based tumor response and clinical benefit.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: James C Yao
Authors: Yao J C, Fazio N, Pavel M, Strosberg J, ...
Keywords: PDR001, immunotherapy, NET